Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, Phase 3 Program fOr Evaluation of TYK2 inhibitor psoriasis second trial
J Am Acad Dermatol 2023;88:40–51. doi: 10.1016/j.jaad.2022.08.061
This Phase 3 study by Strober, et al. reports deucravacitinib superiority to placebo and apremilast in patients with PsO. The authors found that deucravacitinib had significantly higher rates of PASI 75 and sPGA achievement than placebo and deucravacitinib.
Patients were randomised to deucravacitinib, apremilast, or placebo for the first 16 weeks of the study. The placebo group was switched to deucravacitinib from Week 16–52. The deucravacitinib group were rerandomized to placebo or deucravacitinib if they showed improvements in PASI. If their PASI score did not change by ≥75%, patients in the apremilast group were then switched to deucravacitinib.
Keywords:
